$363 Million is the total value of Iguana Healthcare Management, LLC's 133 reported holdings in Q3 2017. The portfolio turnover from Q2 2017 to Q3 2017 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| New | CLOVIS ONCOLOGY INCcall | $12,360,000 | – | 150,000 | +100.0% | 3.41% | – | |
| BMY | New | BRISTOL MYERS SQUIBB CO | $7,012,000 | – | 110,000 | +100.0% | 1.93% | – |
| DHR | New | DANAHER CORP DEL | $6,004,000 | – | 70,000 | +100.0% | 1.66% | – |
| XLRN | New | ACCELERON PHARMA INC | $5,224,000 | – | 140,000 | +100.0% | 1.44% | – |
| FGEN | New | FIBROGEN INC | $4,304,000 | – | 80,000 | +100.0% | 1.19% | – |
| PFE | New | PFIZER INC | $4,284,000 | – | 120,000 | +100.0% | 1.18% | – |
| CAH | New | CARDINAL HEALTH INC | $4,016,000 | – | 60,000 | +100.0% | 1.11% | – |
| ESRX | New | EXPRESS SCRIPTS HLDG CO | $3,166,000 | – | 50,000 | +100.0% | 0.87% | – |
| INSM | New | INSMED INC | $3,122,000 | – | 100,000 | +100.0% | 0.86% | – |
| ARNA | New | ARENA PHARMACEUTICALS INC | $3,060,000 | – | 120,000 | +100.0% | 0.84% | – |
| KURA | New | KURA ONCOLOGY INC | $2,692,000 | – | 180,000 | +100.0% | 0.74% | – |
| TDOC | New | TELADOC INC | $2,320,000 | – | 70,000 | +100.0% | 0.64% | – |
| ASND | New | ASCENDIS PHARMA A Ssponsored adr | $2,176,000 | – | 60,000 | +100.0% | 0.60% | – |
| MRNS | New | MARINUS PHARMACEUTICALS INC | $2,054,000 | – | 350,000 | +100.0% | 0.57% | – |
| SRRA | New | SIERRA ONCOLOGY INC | $1,860,000 | – | 1,200,000 | +100.0% | 0.51% | – |
| FOLD | New | AMICUS THERAPEUTICS INC | $1,810,000 | – | 120,000 | +100.0% | 0.50% | – |
| PRTK | New | PARATEK PHARMACEUTICALS INC | $1,758,000 | – | 70,000 | +100.0% | 0.48% | – |
| New | INCYTE CORPcall | $1,752,000 | – | 15,000 | +100.0% | 0.48% | – | |
| IONS | New | IONIS PHARMACEUTICALS INC | $1,522,000 | – | 30,000 | +100.0% | 0.42% | – |
| New | EXELIXIS INCput | $1,212,000 | – | 50,000 | +100.0% | 0.33% | – | |
| CTLT | New | CATALENT INC | $1,198,000 | – | 30,000 | +100.0% | 0.33% | – |
| VYGR | New | VOYAGER THERAPEUTICS INC | $1,030,000 | – | 50,000 | +100.0% | 0.28% | – |
| New | PTC THERAPEUTICS INCcall | $1,000,000 | – | 50,000 | +100.0% | 0.28% | – | |
| New | IGNYTA INCcall | $618,000 | – | 50,000 | +100.0% | 0.17% | – | |
| ADAP | New | ADAPTIMMUNE THERAPEUTICS PLCsponds adr | $410,000 | – | 50,000 | +100.0% | 0.11% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| BIOGEN INC | 17 | Q1 2018 | 7.5% |
| ULTRAGENYX PHARMACEUTICAL IN | 17 | Q1 2018 | 6.7% |
| MERCK & CO INC NEW | 16 | Q1 2018 | 5.4% |
| CELGENE CORP | 15 | Q4 2017 | 7.9% |
| AERIE PHARMACEUTICALS INC | 15 | Q4 2017 | 3.3% |
| GILEAD SCIENCES INC | 14 | Q1 2017 | 6.7% |
| ESPERION THERAPEUTICS INC NE | 14 | Q1 2018 | 7.8% |
| SUPERNUS PHARMACEUTICALS INC | 14 | Q4 2017 | 2.8% |
| DERMIRA INC | 14 | Q1 2018 | 2.7% |
| AMGEN INC | 13 | Q1 2017 | 6.5% |
View Iguana Healthcare Management, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2018-05-15 |
| 13F-HR | 2018-02-14 |
| 13F-HR/A | 2017-11-16 |
| 13F-HR | 2017-11-14 |
| 13F-HR | 2017-08-14 |
| 13F-HR | 2017-05-15 |
| 13F-HR | 2017-02-14 |
| 13F-HR/A | 2016-11-17 |
| 13F-HR | 2016-11-14 |
| 13F-HR/A | 2016-11-04 |
View Iguana Healthcare Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.